Cyclin-dependent kinase inhibition with roscovitine: neuroprotection in acute ischemic stroke.
Stroke is the third most common cause of mortality and the leading cause of disability in industrialized country. According to population based-studies, ischemic stroke accounts for 67-80% of all strokes. Thrombolysis is used during the acute phase in only 2-5% of ischemic patients. Clinical trials of candidate neuroprotective agents have failed to identify viable therapies for ischemic stroke in humans. There is therefore a great need for new therapeutic strategies, considering that not all brain cells die immediately after ischemic stroke.
CHRU Brest, Hôpital de la Cavale Blanche, Département de Neurologie, Faculté de Médecine et des Sciences de la Santé, INSERM U-613 de Brest, Brest, France. serge.timsit@chu-brest.fr
S
S
Timsit
B
B
Menn
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D008954:Models, Biological; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011687:Purines / Q000494:pharmacology* / Q000627:therapeutic use*; D000077546:Roscovitine; D020521:Stroke / Q000188:drug therapy*
D018696:Neuroprotective Agents; D047428:Protein Kinase Inhibitors; D011687:Purines; D000077546:Roscovitine; D018844:Cyclin-Dependent Kinases